Genzyme, Ablynx collaborate on multiple sclerosis research project

Monday, May 18, 2015

Ablynx, a biopharma company headquartered in Belguim, has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate nanobodies against a multiple sclerosis (MS) target specifically aligning with Genzyme’s early-stage MS research programs involving neuroprotection and CNS repair.

The neurodegeneration observed in MS is not directly targeted by existing treatments. Genzyme’s research efforts aim to address this unmet need by targeting the underlying causes of MS disease progression and by developing treatments to protect neurons and promote repair of CNS damage.

Genzyme will have the right to perform in vitro and in vivo research with Ablynx’s nanobodies in MS-relevant models in return for an exclusivity fee. Genzyme will have the option to negotiate a license agreement upon completion of these studies. Ablynx already has generated potent nanobodies against the specific target of interest and confirmed their activity in pre-clinical models.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news,
emerging trends, and business issues around everything in the rapidly changing clinical research
marketplace. Check out our new CWWeekly page! Sign up today for your
free email newsletter, update your bookmarks and check us out regularly!
We look forward to bringing you the best news and information about
clinical research in 2018!